FIELD: clinical hematology. SUBSTANCE: to activate protein C, protein C activator is added to standard oxalate plasma and factor V-free plasma and then phospholipid membranes of platelets are added to mixture being studied. For diagnostics, one determines normalized ratio as ratio of index Rb for patient's plasma which is ratio of patient's plasma coagulation time, plasma containing no V factor and containing activated protein C to diluted patient's plasma coagulation time, to that of V factor-free plasma, and to index RК for normal plasma. When normalized ratio is less than 0.8, results of test are regarded as positive. EFFECT: simplified procedure, improved specificity and reproducibility. 1 dwg, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF DIAGNOSIS OF THROMBOPHILIA DETERMINED BY RESISTANCE OF FACTOR V TO ACTIVATED PROTEIN C | 2001 |
|
RU2205411C2 |
METHOD FOR CONTROL OF SUBSTITUTIONAL THERAPY EFFICIENCY AT DVS- SYNDROME | 2000 |
|
RU2190855C2 |
METHOD FOR DETERMINING LUPUS ERYTHEMATOSUS ANTICOAGULANT AVAILABILITY | 1999 |
|
RU2181203C2 |
METHOD FOR DIAGNOSING ANTIPHOSPHOLIPID SYNDROME | 1995 |
|
RU2104550C1 |
HEPARIN CONCENTRATION DETERMINATION METHOD | 2003 |
|
RU2249819C2 |
METHOD FOR DIAGNOSING THE CASES OF THROMBOPHILIA CAUSED BY HIGH ACTIVITY LEVEL OF COAGULATION FACTOR VIII | 2002 |
|
RU2227918C1 |
METHOD FOR PREECLAMPSIA PREDICTION IN PREGNANT WOMEN WITH MUTATION OF FACTOR V LEIDEN 1691 GENE OF G/A AND A/A GENOTYPE | 2016 |
|
RU2636228C1 |
METHOD FOR PREGNANCY OUTCOME PREDICTION OF IN CASE THREATENING PREMATURE DELIVERY | 2016 |
|
RU2630573C2 |
METHOD FOR DETERMINATION OF ACTIVATED FACTOR VII IN BLOOD PLASMA | 1991 |
|
RU2034298C1 |
METHOD OF DYSPLASMINOGENEMIA DIAGNOSTICS | 2006 |
|
RU2336529C2 |
Authors
Dates
1999-04-20—Published
1996-08-05—Filed